Isofol Medical AB (publ) banner

Isofol Medical AB (publ)
STO:ISOFOL

Watchlist Manager
Isofol Medical AB (publ) Logo
Isofol Medical AB (publ)
STO:ISOFOL
Watchlist
Price: 0.65 SEK 0.46%
Market Cap: kr182.7m

Multiples-Based Value

The Multiples-Based Value for Isofol Medical AB (publ) (ISOFOL) under the Base Case is hidden SEK. Compared with the current market price of 0.65 SEK, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ISOFOL Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

ISOFOL Competitors Multiples
Isofol Medical AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Isofol Medical AB (publ)
STO:ISOFOL
182.7m SEK 0 -3.4 -0.8 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
374.1B USD 6.1 89.4 14.8 20.5
US
Amgen Inc
NASDAQ:AMGN
188.5B USD 5.1 24.4 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
175.7B USD 6 20.7 12.9 15.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.8B USD 9.4 28.5 21.4 22.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD 5.7 18.2 13.7 15.6
NL
argenx SE
XBRU:ARGX
41.5B EUR 11.7 37.5 40.5 41.4
AU
CSL Ltd
ASX:CSL
68.5B AUD 3 33.2 11.2 14
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
SE
Isofol Medical AB (publ)
STO:ISOFOL
Average P/S: 3 369 303.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
11.7
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
SE
Isofol Medical AB (publ)
STO:ISOFOL
Average P/E: 36
Negative Multiple: -3.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.4
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.7
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.5
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
NL
argenx SE
XBRU:ARGX
37.5
32%
1.2
AU
CSL Ltd
ASX:CSL
33.2
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Isofol Medical AB (publ)
STO:ISOFOL
Average EV/EBITDA: 18.4
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
18%
0.8
NL
argenx SE
XBRU:ARGX
40.5
50%
0.8
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Isofol Medical AB (publ)
STO:ISOFOL
Average EV/EBIT: 20.6
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.5
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.9
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
23%
0.7
NL
argenx SE
XBRU:ARGX
41.4
51%
0.8
AU
CSL Ltd
ASX:CSL
14
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett